Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
- Conditions
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 2900
- Registration Number
- NCT04330690
- Locations
- 🇨🇦
Health Sciences Centre, Winnipeg, Manitoba, Canada
🇨🇦Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Alberta, Canada
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Johnson & Johnson (China) Investment Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04312659
- Locations
- 🇨🇳
Guangzhou Women And Children's Medical Center, Guangzhou, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China
🇨🇳The Children's Hospital, Zhejiang University School Of Medicine, Hangzhou, China
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04305145
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-02-17
- Target Recruit Count
- 32
- Registration Number
- NCT04272788
- Locations
- 🇨🇳
SAHWenzhouMU, Wenzhou, Zhejiang, China
A Clinical Trial of Infliximab for Childhood Uveitis
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Xiaomin Zhang
- Target Recruit Count
- 10
- Registration Number
- NCT04150770
Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 239
- Registration Number
- NCT04131504
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-06-24
- Target Recruit Count
- 120
- Registration Number
- NCT03937609
- Locations
- 🇮🇪
St Vincent's University Hospital, Dublin, Ireland
🇳🇱Academic Medical Center, Amsterdam, Netherlands
🇳🇱OLVG Oost, Amsterdam, Netherlands
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Lung Non-Small Cell CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmPathologic Stage 0 Cutaneous Melanoma AJCC v8Pathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT03819296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Alimentiv Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03765450
- Locations
- 🇺🇸
Cornell University, New York, New York, United States
🇺🇸UCSD, San Diego, California, United States
🇨🇦London Health Sciences Center, London, Ontario, Canada
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 31
- Registration Number
- NCT03704610
- Locations
- 🇫🇷
Hopital de la Timone- service de Médecine Internne, Marseille, France
🇫🇷CHU Hotel Dieu - service de Médecine Interne, Nantes, France
🇫🇷Hopital Henri Mondor- service de Médecine Interne, Créteil, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.